A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Фаза 3
Идёт, набор закрыт
NCT04975308
| Заболевание | Breast Neoplasms, Neoplasm Metastasis |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Eli Lilly and Company |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 874 участн. |
|---|
| Вмешательство | Imlunestrant, Exemestane, Fulvestrant, Abemaciclib |
|---|
| Дата начала | 4.10.2021 |
|---|
| Дата завершения | 24.06.2024 |
|---|
| Публикация результатов | 11.07.2025 |
|---|
Кратко
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)
Randomization to the date of first documented progression of disease or death from any cause (up to 28 months) · Months
| Arm A: Imlunestrant | 5.55 Months |
|---|
| Arm B: Investigator's Choice of Endocrine Therapy | 5.52 Months |
|---|
| p-value | 0.1158 |
|---|
| Hazard Ratio (HR) | 0.867 (95% CI 0.724–1.039) |
|---|
Investigator-assessed PFS (Between Arm C and Arm A)
Randomization to the date of first documented progression of disease or death from any cause (up to 26 months) · Months
| Arm C: Imlunestrant + Abemaciclib | 9.36 Months |
|---|
| Arm A: Imlunestrant | 5.49 Months |
|---|
| p-value | <0.0001 |
|---|
| Hazard Ratio (HR) | 0.569 (95% CI 0.441–0.733) |
|---|
Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)
Randomization to the date of first documented progression of disease or death from any cause (up to 28 months) · Months
| Arm A: Imlunestrant | 5.49 Months |
|---|
| Arm B: Investigator's Choice of Endocrine Therapy | 3.84 Months |
|---|
| p-value | 0.0008 |
|---|
| Hazard Ratio (HR) | 0.617 (95% CI 0.464–0.821) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.